Business Context and Reporting Period
This Form 8-K filing by NanoViricides, Inc. (NYSE American: NNVC) reports on events occurring on February 7, 2023. The filing details the reconvened 2022 Annual Meeting of Stockholders, where shareholders voted on a proposal to redomicile the company from Nevada to Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Shareholders approved the redomicile of the Company to Delaware. The voting statistics for the meeting were as follows:
- Shares Entitled to Vote: 11,610,037 shares of Common Stock and 495,173 shares of Series A Convertible Preferred Stock.
- Attendance: 56% of securities entitled to vote were present in person or by proxy.
- Proposal 1 (Redomicile):
- Votes For: 8,115,210
- Votes Against/Withheld: 942,379
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document strictly reports the outcome of the shareholder vote as described in the Proxy Statement filed on November 15, 2022.
Key Facts for Investor Verification
- Confirm the effective date of the redomicile from Nevada to Delaware.
- Review the November 15, 2022 Proxy Statement for detailed rationale regarding the redomicile.
- Verify the impact of the redomicile on existing Series A Convertible Preferred Stock rights.